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Abstract
Background—accurate prognostic prediction is challenging for advanced-stage non-small cell 
lung cancer (NSCLC) patients.
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Methods—we systematically investigated genetic variants within inflammation pathway as 
potential prognostic markers for advanced-stage NSCLC patients treated with first-line 
chemotherapy. A discovery phase in 502 patients and an internal validation in 335 patients were 
completed at MD Anderson Cancer Center. External validation was performed in 371 patients at 
Harvard University.
Results—a missense SNP (HLA-DOB:rs2071554) predicted to influence protein function was 
significantly associated with poor survival in the discovery (HR:1.46, 95% CI:1.02-2.09), internal 
validation (HR:1.51, 95% CI:1.02-2.25), and external validation (HR:1.52, 95% CI:1.01-2.29) 
populations. KLRK1:rs2900420 was associated with a reduced risk in the discovery (HR:0.76, 
95% CI:0.60-0.96), internal validation (HR:0.77, 95% CI:0.61-0.99), and external validation (HR:
0.80, 95% CI:0.63-1.02) populations. A strong cumulative effect was observed for these SNPs on 
overall survival.
Conclusions—Genetic variations in inflammation-related genes could have potential to 
complement prediction of prognosis.
Keywords
NSCLC; advanced stage; overall survival; inflammation; single nucleotide polymorphism
INTRODUCTION
Lung cancer is a highly lethal disease and was responsible for an estimated 160,000 deaths 
in 2013 in the US (1). Patients are typically diagnosed at advanced stage (stage III/IV) with 
a dismal 5-year survival rate(2). Combination chemotherapy is the standard of care for stage 
IV non-small cell lung cancer (NSCLC), while combined platinum-based chemoradiation or 
chemoradiation/surgery is the standard therapy for stage III NSCLC (3, 4). While some 
patients benefit from standard of care, others do not. Prognostic biomarkers that improve the 
accuracy of outcome prediction for individual patients could be useful clinically.
Inflammation is estimated to contribute to 15% of all cancer deaths (5). The lung is a 
frequent site of inflammation due to environmental exposures, and inflammatory diseases of 
the lung, such as chronic obstructive pulmonary disease, have been related to increased 
incidence and a poor prognosis of lung cancer (6, 7). Evidence has shown that inflammatory 
molecules and effectors are independently associated with tumor progression and survival in 
advanced-stage lung cancer patients (8, 9). Moreover, chemotherapeutic agents are known to 
induce cellular damage, which could trigger an acute inflammatory response (10, 11). 
Uncontrolled inflammation can attenuate treatment effectiveness and lead to the 
development of chemoresistance (12) or toxicities, both of which worsen prognosis (13). 
Taken together, these findings suggest that genetic markers of inflammation might be 
promising prognostic biomarkers for patients with advanced lung cancer.
Genome-wide association studies (GWAS) have recently been used to detect loci as 
potential biomarkers of risk and outcomes for various diseases, including lung cancer 
(14-19). However, some genomic regions have relatively low coverage due to weak linkage 
disequilibrium relationships and the design of the GWAS arrays. Thus, a comprehensive 
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evaluation of genetic regions of interest based on prior knowledge of the disease biology 
utilizing pathway-based or gene-based approaches are needed to compliment GWAS 
findings (20). Towards this, we conducted a multi-phase, pathway-based study to evaluate 
single nucleotide polymorphisms (SNPs) in major inflammation genes for their effect on 
overall survival in patients with advanced NSCLC treated with first-line primary 
chemotherapy (either alone or in combination with radiotherapy), with the goal of 
identifying potential prognostic biomarkers that will benefit this group of patients.
RESULTS
Patient characteristics
A total of 837 (discovery: 502, validation: 335) patients from MD Anderson and 371 
patients from Harvard were included in the analysis (Table 1). MD Anderson populations 
have a relatively longer median survival time (MST) (discovery: 16.5 months, validation: 
16.8 months) compared to the Harvard population (12.2 months). The median follow-up 
time of patients in MD Anderson discovery phase is relatively short (30.5 months) which is 
probably due to the higher percentage of stage IV patients. All the patients were non-
Hispanic whites with Stage III or IV NSCLC and age was not significantly different 
between patients who had died and those who were alive.
Association of inflammation-related SNPs on overall survival
A total of 11,930 SNPs from 904 genes were genotyped, of which 11,689 passed quality 
control measures and were included in the MD Anderson discovery analysis (Figure 1). 
1,123 SNPs were significantly associated with overall survival in this group (P<0.05). 
Among these SNPs, genotyping data from a previously published GWAS (19) was available 
for 267 SNPs. After removing 413 SNPs which had insignificant (P<0.2) proxy SNPs 
(r2>0.8) on the GWAS chip, we genotyped an additional 443 SNPs using a custom designed 
iSelect BeadChip.
After quality control, 657 SNPs (390 genotyped and 267 using existing genotype data) were 
selected for analysis in the internal validation. We validated the association with overall 
survival for 49 SNPs (HRs consistent and P < 0.05 in both phases). We then performed an 
external validation of 32 of the 49 SNPs (those that had existing data available from 
previously published GWAS) in the Harvard population (17). Seventeen SNPs were found 
to have consistent effects on overall survival in all three populations, with two significant (or 
borderline significant) in all three phases (Table 2).
Rs2071554, a missense variation in the first exon of HLA-DOB (major histocompatibility 
complex class II, DO beta), was associated with increased risk of death in all three 
populations (Figure 2a). In the MD Anderson discovery population (HR=1.46, 95% 
CI=1.02- 2.09, P=0.040), patients carrying at least one variant allele (AG or AA) had a 
significant survival disparity of six months, from 17 months to 11 months, compared with 
those who were homozygous for the common allele (GG, P for log-rank test=0.009, Figure 
3a). In the MD Anderson internal validation population, rs2071554 was also associated with 
increased risk of death (HR=1.51, 95% CI=1.02-2.25, P=0.041), and a non-significant, but 
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appreciable seven month shortened MST (Figure 3b). A similar effect was observed in the 
Harvard external validation population. The variant allele was associated with shortened 
overall survival (HR=1.52, 95% CI=1.01- 2.29, P=0.045); patients carrying at least one copy 
of the variant allele had a shorter MST than patients who were homozygous for the common 
allele (P for log-rank test=0.007; Figure 3c). Meta-analysis of the association of rs2071554 
with overall survival under the fixed effects model showed a P value of 4.3×10−4 (HR=1.49, 
95% CI=1.19-1.87, P for heterogeneity=0.988, Figure 2a).
KLRK1:rs2900420, which is located in the 3′ flanking region of the KLRK1 (killer cell 
lectin-like receptor subfamily K, member 1) gene, a component of the natural killer cell 
signaling pathway, was associated with reduced risk in the MD Anderson discovery 
population (HR=0.76, 95% CI=0.60-0.96, P=0.021) and in the MD Anderson internal 
validation population (HR=0.77, 95% CI=0.61-0.99, P=0.038), while borderline significant 
in Harvard external validation population (HR=0.80, 95% CI=0.63-1.02, P=0.069; Figure 
2b). Significant survival time advantages were observed for patients who carried at least one 
variant allele compared with patients who were homozygous for the common allele 
(discovery: GG, 15 months; AG and AA, 20 months; P for log-rank test=0.011; internal 
validation: GG, 15 months; AG and AA, 18 months; P for log-rank test=0.087). In the 
Harvard external validation population, the association of rs2900420 with overall survival 
reached borderline significance (HR=0.80, 95% CI=0.63-1.02, P=0.069). However, meta-
analysis of the validation populations showed a significant effect (P=0.006) and in the 
overall meta-analysis the effect was highly significant at p=3.5×10−4 (HR=0.78, 95% 
CI=0.68-0.89, P for heterogeneity=0.945).
In addition, ten other variants were significant in the MD Anderson discovery and internal 
validation populations and did not reach significance in the Harvard external validation, but 
did show significance in a meta-analysis of the validation results and the overall meta-
analysis.
Cumulative effects
In the cumulative effects analysis, we observed a significant “SNP-dosage” effect of these 
SNPs on overall survival: the more risk genotypes a patient carried, the greater the 
deleterious effects on overall survival (Figure 2c). Compared to individuals without any 
UFGs, patients carrying one UFG had combined 31% increased risk of death (MD Anderson 
discovery: HR=1.37, 95% CI=1.07-1.76, P=0.013; MD Anderson internal validation: 
HR=1.32, 95% CI=1.03-1.71, P=0.031; Harvard external validation: HR=1.25, 95% 
CI=0.98-1.60, P=0.073). This raised to an 83% increase in risk in the overall population for 
those with two UFG (MD Anderson discovery: HR=1.83, 95% CI=1.14-2.94, P=0.012; MD 
Anderson internal validation: HR=1.96, 95% CI=1.17-3.30, P=0.011; Harvard external 
validation: HR=1.75, 95% CI=1.07-2.85, P=0.025) and significantly decreased median 
survival times (Figure 4).
in silico function analysis of HLA-DOB rs2071554
To determine the potential consequences of this variant and explore the underlying 
mechanism, we applied bioinformatics tools to in silico evaluate the effect on protein 
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structure and function. rs2071554 is a missense variation that results in an arginine to 
glutamine substitution in the first exon of HLA-DOB. Polyphen2 analysis suggested that this 
amino acid change may potentially damage protein function (Polyphen2: 0.923, sensitivity: 
0.80, specificity: 0.94). Similarly, SIFT predicted this SNP to be deleterious (SIFT score: 
0.02). Both tools provide additional evidence in support of the potential importance of this 
SNP on protein function.
DISCUSSION
We systematically evaluated the effects of SNPs from major inflammation genes on overall 
survival of advanced NSCLC patients who received first-line chemotherapy. In our 3-phase 
pathway-based association study, we identified two potential prognostic biomarkers: HLA-
DOB:rs2071554 and KLRK1:rs2900420. HLA-DOB variant increased risk with a 
corresponding decrease in median survival time, while the KLRK1 SNP was protective and 
prolonged overall survival. Moreover, the HLA-DOB variant was predicted to alter function 
through in silico analysis, consistent with the observed association of increased risk of death 
and shortened survival time.
HLA-DOB is the beta subunit of the HLA-DO class II paralogs. It functions as a negative 
regulator of major histocompatibility complex class II molecules by inhibiting HLA-DM 
molecules in a pH-dependent manner. The DO:DM ratio dictates major histocompatibility 
complex class II restricted-antigen presentation efficiency (21). Evidence has shown that 
dysregulation of the antigen presentation pathway is involved in cancer development (22). 
Moreover, major histocompatibility complex class II molecules are key immune response 
molecules, which have been reported to have a positive relationship with prognosis in 
various cancers (23, 24). In our study, we determined that this missense SNP may alter 
protein structure and function, and we identified a robust adverse effect on survival across 
all three populations. Currently, no studies have implicated this gene as playing a role in 
lung cancer risk or clinical outcomes. Our results suggest a potential predictive role of this 
locus, making it worthy of future deep sequencing to identify the causal variant and 
functional analysis in vitro to elucidate the mechanisms responsible.
KLRK1 (member 1 of the killer cell lectin-like receptor subfamily K) encodes for a 
transmembrane protein that interacts with various ligands to activate natural killer and T 
cells, leading to lysis of targeted cells, including tumor cells. This gene has been previously 
shown to be involved in chemoresistance for osteosarcoma (25) and ligands binding to 
KLRK1 have been found to prevent cisplatin-induced cytotoxic lymphocyte killing (26). 
Studies have also reported that lung adenocarcinoma cells were able to escape from the 
innate immune response of natural killer cells by expressing heterogeneous ligands for 
KLRK1 (27). Furthermore, this gene has been identified as a promising target for 
immunotherapy for cancer (28, 29). However, similar to HLA-DOB, no previous studies 
have linked KLRK1 to lung risk or clinical outcomes, highlighting the ability of targeted 
approaches in identifying novel predictors. KLRK1:rs2900420 is located three kilobases 3′ to 
the KLRK1 gene. In our study, it was associated with prolonged overall survival in the MD 
Anderson populations and its association with prolonged overall survival was nearly 
significant in the Harvard external validation population. It is very likely that with increased 
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sample size the results would reach statistical significance. An additional KLRK1 variant 
(rs7972757) was significant in the MD Anderson discovery and internal validation 
populations, but not replicated in the Harvard external validation, providing additional 
support to the potential importance of this gene in lung cancer. Further exploration of the 
potential underlying biological mechanism(s) of this association would increase our 
understanding of this relationship and solidify the role of KLRK1 in lung cancer prognosis.
To minimize differences in tumor characteristics and treatment regimens between the two 
study sites (MD Anderson and Harvard), we followed strict inclusion criteria based on stage 
and treatment. For example, a majority (>80%) of the patients in all three study populations 
were treated with platinum-based chemotherapy (Table 1), most commonly with the 
addition of a taxane although other agents included pemetrexed, gemcitabine, bevacizumab, 
and erlotinib. However, even with these measures in place, there are always subtle, often 
unidentifiable, differences in the patient populations among different hospitals, which could 
result in differences in survival times as we observed between the MD Anderson and 
Harvard cohorts. For example, patients who died at Harvard cohort were at a slightly older 
age (63.6 years in Harvard, compared to 60.7 years in MD Anderson discovery and 59.3 
years in MD Anderson validation). These slight differences in the populations underscore 
the potential impact of the two validated SNPs - the effects are stronger than any differences 
among the study populations making the findings more transferable across the general 
population of lung cancer patients and not study site specific. Several other genetic variants 
in inflammation genes were significant in the MD Anderson discovery and validation 
populations, but did not reach significance in the Harvard external validation. Ten did 
become significant in the validation meta-analysis (Table 2), suggesting that they may 
indeed be additional predictors of overall survival. These candidate variants are located in 
several well-known inflammation genes, including the receptors for several circulating 
cytokines (CSF1R, IL21R, IL17RA), cytokines (IRF2, IFNA14), and cellular signaling 
molecules (PRKCE, PRKCZ). Further analysis of these genetic variants and genes would be 
of interest to definitively establish or abolish a relationship with overall survival in advanced 
lung cancer patients.
To our knowledge, this is the first study to systematically investigate the effects of 
inflammation-related genetic variations on survival of advanced NSCLC patients. The major 
strength of this study was the three-phase screening and validation approach using two 
independent patient populations, which were drawn from the largest lung cancer 
pharmacogenetic clinical outcome studies in the United States. All patients were at advanced 
stages treated with first line chemotherapy with or without radiotherapy. In addition, we 
developed a comprehensive panel of inflammation-related genetic variations, which covered 
major cellular processes involved in inflammation responses and regulatory processes. With 
this extensive coverage, our results provide a broad overview of the role of genetic variation 
within the overall inflammation network in modulating patients’ clinical outcomes.
In conclusion, we identified and validated two potential genetic markers within the 
inflammation pathway that may affect overall survival in patients with advanced NSCLC 
treated with first-line chemotherapy. Given the important role of inflammation throughout 
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the cancer continuum, these genetic markers may be promising prognostic markers to help 
in treatment decision-making in the clinic.
METHODS
Study populations and data collection
MD Anderson discovery and validation populations—Patients from The University 
of Texas MD Anderson Cancer Center included in this study are part of an ongoing lung 
study that has been recruiting since 1995. All patients were non-Hispanic white, had 
histologically confirmed advanced-stage (stage III or IV, AJCC v6.) NSCLC, did not 
undergo surgery, and received first-line chemotherapy with or without radiotherapy at MD 
Anderson. A total of 502 patients were included in the discovery population with an 
additional 335 in the validation analysis. A structured questionnaire was used to collect 
epidemiologic and demographic data during an in-person interview. In addition, genomic 
DNA was extracted from peripheral blood samples using the QIAamp DNA extraction kit 
(Qiagen, Valencia, CA). Clinical and follow-up data were obtained from medical records. 
Each patient signed informed consent, and this study was approved by the MD Anderson 
Institutional Review Board.
Harvard external validation—The details of the Harvard lung cancer population have 
been described in detail previously (30). In brief, participants were non-Hispanic white 
patients newly diagnosed with histologically confirmed lung cancer. From this population, 
we selected patients with advanced NSCLC who had received first-line chemotherapy with/
without radiation therapy and had not undergone surgery were included in the external 
validation population. A total of 371 patients met these criteria. An interviewer-administered 
questionnaire was used to collect epidemiologic data. Peripheral blood was drawn for DNA 
extraction. Informed consent was signed by each study participant and Harvard Institutional 
Review Board approved this study.
Genotyping and quality control
MD Anderson discovery—A custom Illumina iSelect genotyping BeadChip was 
designed to genotype genetic variants in inflammation-related genes (study design detailed 
in Figure 1). Genes involved in inflammatory responses and regulation were retrieved using 
the T1Dbase (http://www.t1dbase.org; University of Cambridge), which focuses on 
diabetes-related and inflammation-related genes. Additional gene information was obtained 
from the WKINFLAM panel (31). Tagging SNPs for each gene were selected from within a 
10-kb flanking region using CEU data from the HapMap Project (http://www.hapmap.org), 
based on the NCBI B36 assembly and dbSNP b126 using the Tagger Pairwise method (r2> 
0.8 and minor allele frequency [MAF]≥0.05) (32). Candidate SNPs were then submitted to 
Illumina (San Diego, CA) and tested for designability using the Assay Design Tool. SNPs 
with a score >0.6 were considered qualified for the creation of the iSelect BeadChip.
Detailed genotyping and quality control methods used in the discovery phase have been 
previously described (33). Briefly, genotyping was performed according to the standard 
Infinium II assay protocol for the iSelect HD BeadChips. Quality control measures were 
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applied to the datasets, excluding any DNA samples or SNPs with a call rate (percentage of 
data available for all SNPs or samples) <95%. For patients with direct relatives also enrolled 
in the study, only one patient within the relationship, the one whose DNA sample had a 
higher SNP call rate was included in the final analysis. SNPs with MAF <0.01 were 
excluded.
MD Anderson internal validation—Genotyping for SNPs selected for the validation 
phase was done either through the design of a custom iSelect BeadChip or using existing 
HumanHap300/HumanHap317/HumanHap660 genotyping data. Quality control for the 
iSelect BeadChip was performed on the basis of sample and SNP call rates; we removed any 
samples or SNPs with a call rate <95%. Detailed quality control measures for the 
HumanHap300/HumanHap317/HumanHap660 BeadChip have been described previously; 
these were also based on genotyping call rate (call rate >95% for all samples and SNPs 
included). SNPs with MAF<0.01 were also excluded (34).
Harvard external validation—Genotypes for external validation were obtained from the 
Illumina HumanHap610-Quad chip following standard protocol, as previously described 
(18). Quality control measures were similar to those used in the MD Anderson populations: 
only SNPs and samples with a genotyping call rate >95% and SNPs with MAF>0.01 were 
included in the analysis.
Statistical analyses
For each phase, multivariable Cox proportional hazards regression models, with 
corresponding hazard ratios (HRs) and 95% confidence intervals (CIs), were used to 
estimate the effect of a single SNP on overall survival (the time between diagnosis and death 
or last follow-up), adjusting for age at diagnosis, sex, smoking status (current, former, or 
never), clinical stage (stage III or IV), and treatment regimen (chemotherapy and/or 
radiotherapy). Patients who had smoked fewer than 100 cigarettes over their lifetime were 
defined as never-smokers; ever-smokers were defined as patients who had smoked > 100 
cigarettes over their lifetime, including former smokers (those who had quit smoking >1 
year before diagnosis), and current smokers and recent quitters (those who had quit smoking 
within a year before diagnosis).
Kaplan-Meier survival curves and corresponding log-rank tests were used to test the survival 
difference between genotypes of each SNP. Meta-analysis was performed to obtain 
summary HRs and 95% CIs. Heterogeneity was tested with chi-square-based Q-statistics. A 
fixed-effect model was used when heterogeneity was absent (P for heterogeneity >0.05).
The cumulative effect of the top two validated SNPs within each population was determined 
by counting the number of risk genotypes each patient carried and using patients without 
any risk genotypes as a reference group. Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/
index.shtml) (35) and SIFT (http://sift.bii.a-star.edu.sg/) (36) were used in silico to predict 
the influence of the SNP on protein function.
The potential effect of population stratification was evaluated using quantile-quantile plots 
of the test statistics in the MD Anderson discovery population. We calculated the inflation 
Pu et al. Page 8
Clin Pharmacol Ther. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
factor (λ) by dividing the observed median of test statistics by expected median (from χ2 
distribution with 1 degree of freedom) value. The obtained λ is close to 1 (0.92), indicating 
that population substructure has no substantial effect on the test statistics in the discovery 
stage analysis.
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STUDY HIGHLIGHTS
What is the current knowledge on the topic?
For advanced-stage NSCLC patients, platinum-based chemotherapy is the standard of 
care. However, a major hurdle is variation in response and thus, the ability to predict 
prognosis for these patients to enable selection of optimal treatment regimens.
What question did this study address?
This study aimed to identify accurate biomarkers that can be used to guide identification 
of advanced-stage NSCLC patients who would benefit from standard of care, as well as 
those who are at increased risk of a poor outcome under the same treatment regimen.
What this study adds to our knowledge?
Two common germline genetic variants in inflammation-related genes were identified as 
being consistently associated with survival in advanced-stage NSCLC patients treated 
with first-line chemotherapy. Furthermore, this study is the first to implicate HLA-DOB 
and KLRK1 as being involved in lung cancer outcomes.
How this might change clinical pharmacology and therapeutics?
These novel loci have potential to complement clinicopathological variables in prediction 
of prognosis. This would assist the personalization of treatment regimens for those 
predicted to have a poor outcome.
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Figure 1. 
Schematic of study design, SNP selection, and populations for MD Anderson discovery, MD 
Anderson internal validation, and Harvard external validation.
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Figure 2. 
Forest plot for meta-analysis of the association of single nucleotide polymorphisms (A) 
HLA-DOB:rs2071554 and (B) KLRK1:rs2900420, as well as (C) cumulative effect, with 
overall survival in discovery and internal validation populations from MD Anderson and 
external validation population from Harvard. HR, hazard ratio; CI, confidence interval; 
NSCLCs, number of patients with non-small cell lung cancer.
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Figure 3. 
Kaplan-Meier estimates of HLA-DOB:rs2071554 genotypes and overall survival in 
advanced NSCLC patients treated with chemotherapy: (A) MD Anderson discovery; (B) 
MD Anderson internal validation; (C) Harvard external validation. N=A/B, A: number of 
patients dead, B: total number of patients. MST: median survival time.
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Figure 4. 
Kaplan-Meier estimates of UFGs and overall survival in advanced NSCLC patients treated 
with chemotherapy: (A) MD Anderson discovery; (B) MD Anderson internal validation; (C) 
Harvard external validation. N=A/B, A: number of patients dead, B: total number of 
patients. MST: median survival time.
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